Average new-patient physician appointment wait across six specialties in 15 major metro areas.
Why China
Why China can deserve serious comparison.
You may have waited months without a clear next step. Or you may already have a treatment plan, but the cost makes it hard to begin. We help investigate whether China is a serious route worth comparing.
Access pressure
Waiting is not just a delay when a decision has to be made.
Patients usually begin comparing China when the current path feels too slow, too expensive, or too uncertain to accept without a second route to evaluate.
Median referral-to-treatment wait for incomplete pathways at the end of January 2026.
Median wait from GP referral to treatment in the 2025 national physician survey.
Reported median wait for MRI scans in the same 2025 survey.
Data sources:
AMN Healthcare 2025, NHS England January 2026, Fraser Institute 2025.
Comparison frame
China enters the conversation when speed, cost, and clinical depth may change the decision.
Not because China is better in every case, but because some routes are fast enough, serious enough, and financially workable enough to compare.
Medical speed
Specialist review, diagnostics, or planning may move faster when the route is real.
Workable cost
Self-pay families may compare China against Western private-care costs.
Clinical depth
Large tertiary centers can offer specialist volume and department execution.
Guided route
The question is whether capacity fits one diagnosis, timeline, and family decision.
The task is to compare the route, not to assume the answer.
Cost comparison
Cost does not decide the route, but it can change the question.
Some checks, procedures, and advanced therapies may deserve a real cost comparison before a family rules out China completely.
Diagnostic colonoscopy
Screening costs can become a decision trigger.
Useful for understanding why digestive screening or diagnostic workups can create cost pressure for self-pay patients.
Hip replacement
Out-of-pocket surgery quotes change the conversation.
Orthopedic cost comparison depends heavily on implant choice, hospital level, complications, and rehab plan.
CAR-T medicine only
For oncology patients and caregivers, drug price is only the first question.
Drug-only benchmarks can differ substantially, but eligibility, hospital pathway, toxicity management, and follow-up determine whether comparison is meaningful.
PET-CT imaging
High-end imaging has to be compared with context.
Converted from public Shanghai PET-CT references around RMB 7,000-13,000. Timing, oncology context, and report quality still matter.
China-side figures are converted at USD:RMB = 1:7 for easier comparison.
Need to know whether a cost comparison is relevant to your case?
Ask if your case fits
Data sources:
GoodRx colonoscopy cost guide, Baidu Health Shanghai colonoscopy reference, Cost Digest hip replacement guide, Youlai China hip replacement reference, HM Insurance Group 2025 CAR-T update, The Paper CAR-T price report, Baidu Health axicabtagene price reference, Baidu Health relma-cel price reference, BetterCare PET scan cost guide, Baidu Health Shanghai PET-CT reference.
Service capacity
Scale matters only when it becomes access.
Our working files track China international-care signals such as foreign-patient volume, service networks, and Shanghai delivery capacity.
International patient visits across key China hospitals in 2025, according to reviewed industry materials.
57 cities and 850 institutions with international medical-service signals in the same research set.
International medical departments or centers tracked in reviewed China service-capacity materials.
International green-channel diagnostic timing signal from Shanghai service-delivery research.
Data sources:
Reviewed China international-medical industry materials and Shanghai international-care delivery research.
How to read these numbers
Western wait-time figures are public benchmarks. China service-capacity figures are directional research signals from materials reviewed by YourChinaMed. They are useful for deciding what to verify next, not for promising access.
Clinical depth
Modern medical capacity, not just lower cost.
China's case for comparison is also about system scale, specialist volume, regulated innovation, and frontier-treatment research.
China reported 4,111 tertiary hospitals in 2024, including 1,876 Grade-A tertiary hospitals.
Tertiary hospitals accounted for 2.87 billion visits in 2024, a signal of high specialist-system throughput.
China reported 5.082 million licensed physicians and assistant physicians, plus 5.855 million registered nurses.
NMPA had approved 296 innovative medical devices by 2024, including magnetic-levitation artificial hearts, carbon-ion therapy systems, brain stimulators, PET-CT imaging, AI-assisted diagnostics, and advanced implant devices.
What this adds to the comparison
These figures support a more serious view of China as a modern medical system, not only a lower-cost destination. The next question is whether one hospital, doctor, or treatment route fits one case.
Capacity and innovation sources: NHC 2024 Statistical Communique, People's Daily / NMPA innovation-device briefing.
For oncology patients, caregivers, and complex-case families
Advanced-care verification
Advanced-care signals need a pathway, not just interest.
For complex cases, the most important question is whether the therapy is medically relevant, legally available, financially realistic, and clinically responsible for the actual case.
Particle therapy
Shanghai Proton and Heavy Ion Hospital reported 6,796 discharged patients over nine years, with annual treatment volume above 1,000 cases and nearly 50 treatable tumor categories.
Cell therapy research
Global cancer cell-therapy trials exceeded 6,000 by June 2025. China is one of the most active countries in immune-cell therapy research, with 489 products in clinical trials reported by one 2024-end review.
Regulated access matters
CAR-T, cell therapy, particle therapy, and other frontier options depend on indication, trial criteria, hospital capability, regulatory pathway, payment, and follow-up risk.
How to read advanced-care signals
Advanced-treatment data can sound impressive but may not apply to a patient's diagnosis. We treat these as signals for targeted verification.
Advanced-care sources: Shanghai proton/heavy-ion clinical data, Shanghai treatable disease-scope update, Nature Reviews Drug Discovery 2025, Life Science immune-cell therapy review.
Have an oncology or complex-care question that may involve China?
Ask if your case fitsFit boundaries
China is likely not the right route if...
A serious comparison should also help people rule China out when the burden, timing, or clinical fit does not make sense.
The case is medically unstable
Emergency care, immediate surgery, or acute deterioration usually belongs in the nearest appropriate medical system.
The route depends on a promise
If access, outcome, trial eligibility, or specialist availability cannot be verified, the route should not move forward.
The travel burden outweighs the gain
Some cases are better handled locally when continuity, frailty, language risk, or family logistics make travel unsafe or unreasonable.
What a real comparison can look like.
Illustrative route patterns show how timing, cost, and clinical fit are evaluated without turning the page into a case-story sales pitch.
Digestive screening under cost pressure
A self-pay family compares local colonoscopy pricing with a Shanghai diagnostic route, then verifies timing, anesthesia, pathology reporting, and follow-up before deciding.
Orthopedic pain with long waits
A patient facing months of pain does not just compare surgery price. The route has to confirm implant plan, surgeon fit, rehab needs, and travel safety.
Oncology question with advanced-care interest
A caregiver asks whether CAR-T, particle therapy, or another China option is relevant. The first task is eligibility and risk verification, not booking travel.
Next-step questions
A serious comparison should end in better questions, not a slogan.
Department depth
Is the department strong for this condition or procedure?
Scheduling reality
Can the route move fast enough and still be responsible?
Communication quality
Will reports, records, translation, and family communication hold up?
Reasonable tradeoffs
Do benefits justify time, cost, travel burden, and continuity risks?